KeyCorp Reports First Quarter 2011 Net Income of $184 Million
KeyCorp Reports First Quarter 2011 Net Income of $184 Million
-
Read more on PR Newswire via Yahoo! Finance
Categories: Stock Trading Systems Tags: $184, 2011, First, Income, KeyCorp, Million, Quarter, Reports
Categories: Stock Trading Systems Tags: Avamar, Introduces
Categories: Stock Trading Systems Tags: Introduces
Funds Advised by Apax Partners Announce Early Termination of HSR Waiting Periods for the Acquisitions of Epicor …
Funds Advised by Apax Partners Announce Early Termination of HSR Waiting Periods for the Acquisitions of Epicor …
In connection with the previously announced agreements to acquire Epicor Software Corporation and Activant Group Inc., Element Merger Sub, Inc. , Eagle Parent, Inc. and Epicor today announced that the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended , with respect to the acquisitions of each of Epicor and Activant have been early terminated. Â Element …
Read more on PR Newswire via Yahoo! Finance
Categories: Stock Trading Systems Tags: acquisitions, Advised, Announce, Apax, early, Epicor, funds, Partners, Periods, Termination, waiting
TD Ameritrade Delivers Record Asset Gathering
TD Ameritrade Delivers Record Asset Gathering
OMAHA, Neb.–(BUSINESS WIRE)–TD Ameritrade announces its financial results, and other related business updates, for its second quarter of fiscal 2011.
Read more on Business Wire
Categories: Stock Trading Systems Tags: Ameritrade, Asset, Delivers, Gathering, Record
The Raider in Winter: Carl Icahn at 75
The Raider in Winter: Carl Icahn at 75
Midway through his eighth decade, Carl C. Icahn has begun to contemplate his legacy, and the future of the Icahn empire hangs in the balance.
Read more on The Tuscaloosa News
Categories: Stock Trading Systems Tags: Carl, Icahn, Raider, winter
Google, Fifth Third: Analysts’ New Ratings
Google, Fifth Third: Analysts’ New Ratings
Editor’s Note: Green and red arrows refer to intraday stock price movement. NEW YORK (TheStreet) — CHANGE IN RATINGS Auxilium Pharmaceuticals rated new Buy at UBS. $30 price target. The company’s two lead products are underappreciated by the market…. Click to view a price quote on GOOG . Click to research the Internet industry.
Read more on TheStreet.com
